Correlation between FCGR3A and FCGR2A genotypes and clinical characteristics
| . | FCGR3A . | FCGR2A . | ||||||
|---|---|---|---|---|---|---|---|---|
| VV, n (%) . | VF, n (%) . | FF, n (%) . | P . | HH, n (%) . | HR, n (%) . | RR, n (%) . | P . | |
| No. of patients | 68 (15) | 215 (47) | 177 (38) | * | 122 (27) | 226 (50) | 102 (23) | * |
| Europe | 53 (14) | 181 (47) | 148 (39) | — | 100 (27) | 184 (49) | 89 (24) | — |
| Australia | 15 (19) | 34 (44) | 29 (37) | — | 22 (29) | 42 (55) | 13 (17) | — |
| Male sex | 38 (56) | 120 (56) | 96 (54) | .94 | 62 (52) | 129 (57) | 57 (56) | .61 |
| Age > 60 y | 26 (38) | 90 (42) | 63 (36) | .44 | 43 (35) | 95 (42) | 38 (37) | .42 |
| Ann Arbor stage III/IV | 63 (93) | 195 (91) | 161 (91) | .88 | 115 (94) | 203 (90) | 92 (90) | .35 |
| ECOG PS ≥ 1 | 22 (32) | 69 (32) | 56 (31) | .91 | 31 (25) | 79 (35) | 34 (33) | .43 |
| B symptoms present | 16 (24) | 60 (28) | 47 (27) | .77 | 32 (26) | 60 (27) | 30 (29) | .83 |
| BM involvement | 38 (58) | 113 (53) | 101 (58) | .70 | 74 (62) | 122 (55) | 52 (51) | .58 |
| Elevated LDH | 16 (24) | 67 (31) | 65 (37) | .13 | 35 (29) | 74 (33) | 35 (29) | .71 |
| Hemoglobin level < 12 g/dL | 18 (26) | 39 (18) | 25 (14) | .07 | 22 (18) | 40 (18) | 17 (17) | .96 |
| β2-microglobulin ≥ 3 mg/L | 18 (28) | 52 (26) | 49 (30) | .69 | 26 (22) | 58 (28) | 31 (33) | .23 |
| FLIPI score | ||||||||
| 0-1 risk factors | 17 (25) | 51 (24) | 39 (22) | .64 | 26 (21) | 52 (23) | 27 (26) | .85 |
| 2 risk factors | 20 (29) | 71 (33) | 69 (39) | 47 (39) | 78 (35) | 33 (32) | ||
| 3-5 risk factors | 31 (46) | 92 (43) | 69 (39) | 49 (40) | 95 (42) | 42 (41) | ||
| Induction regimen | ||||||||
| R-CHOP | 54 (79) | 175 (81) | 145 (82) | .55 | 97 (80) | 181 (80) | 87 (85) | .23 |
| R-CVP | 13 (19) | 40 (19) | 31 (18) | 23 (19) | 45 (20) | 15 (15) | ||
| R-FCM | 1 (1) | 0 (0) | 1 (1) | 2 (2) | 0 (0) | 0 (0) | ||
| . | FCGR3A . | FCGR2A . | ||||||
|---|---|---|---|---|---|---|---|---|
| VV, n (%) . | VF, n (%) . | FF, n (%) . | P . | HH, n (%) . | HR, n (%) . | RR, n (%) . | P . | |
| No. of patients | 68 (15) | 215 (47) | 177 (38) | * | 122 (27) | 226 (50) | 102 (23) | * |
| Europe | 53 (14) | 181 (47) | 148 (39) | — | 100 (27) | 184 (49) | 89 (24) | — |
| Australia | 15 (19) | 34 (44) | 29 (37) | — | 22 (29) | 42 (55) | 13 (17) | — |
| Male sex | 38 (56) | 120 (56) | 96 (54) | .94 | 62 (52) | 129 (57) | 57 (56) | .61 |
| Age > 60 y | 26 (38) | 90 (42) | 63 (36) | .44 | 43 (35) | 95 (42) | 38 (37) | .42 |
| Ann Arbor stage III/IV | 63 (93) | 195 (91) | 161 (91) | .88 | 115 (94) | 203 (90) | 92 (90) | .35 |
| ECOG PS ≥ 1 | 22 (32) | 69 (32) | 56 (31) | .91 | 31 (25) | 79 (35) | 34 (33) | .43 |
| B symptoms present | 16 (24) | 60 (28) | 47 (27) | .77 | 32 (26) | 60 (27) | 30 (29) | .83 |
| BM involvement | 38 (58) | 113 (53) | 101 (58) | .70 | 74 (62) | 122 (55) | 52 (51) | .58 |
| Elevated LDH | 16 (24) | 67 (31) | 65 (37) | .13 | 35 (29) | 74 (33) | 35 (29) | .71 |
| Hemoglobin level < 12 g/dL | 18 (26) | 39 (18) | 25 (14) | .07 | 22 (18) | 40 (18) | 17 (17) | .96 |
| β2-microglobulin ≥ 3 mg/L | 18 (28) | 52 (26) | 49 (30) | .69 | 26 (22) | 58 (28) | 31 (33) | .23 |
| FLIPI score | ||||||||
| 0-1 risk factors | 17 (25) | 51 (24) | 39 (22) | .64 | 26 (21) | 52 (23) | 27 (26) | .85 |
| 2 risk factors | 20 (29) | 71 (33) | 69 (39) | 47 (39) | 78 (35) | 33 (32) | ||
| 3-5 risk factors | 31 (46) | 92 (43) | 69 (39) | 49 (40) | 95 (42) | 42 (41) | ||
| Induction regimen | ||||||||
| R-CHOP | 54 (79) | 175 (81) | 145 (82) | .55 | 97 (80) | 181 (80) | 87 (85) | .23 |
| R-CVP | 13 (19) | 40 (19) | 31 (18) | 23 (19) | 45 (20) | 15 (15) | ||
| R-FCM | 1 (1) | 0 (0) | 1 (1) | 2 (2) | 0 (0) | 0 (0) | ||
ECOG indicates Eastern Cooperative Oncology Group; PS, performance status; BM, bone marrow; LDH, lactate dehydrogenase; FLIPI, follicular lymphoma international prognostic index; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; R-CVP, rituximab, cyclophosphamide, vincristine, and prednisone; and R-FCM, rituximab, fludarabine, cyclophosphamide, and mitoxantrone.
The 2 single nucleotide polymorphisms in FCGR3A and FCGR2A were tested for Hardy-Weinberg equilibrium.